Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of August 2022, specifically reporting transaction notifications for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing was submitted on August 22, 2022.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed by company insiders.
| Insider Name | Position | Transaction Date | Instrument | Price (USD) | Volume (ADSs) | Nature of Transaction |
|---|---|---|---|---|---|---|
| Dr H Barron | Non-Executive Director | 2022-08-18 | ADSs | $34.2500 | 3,093.611 | Acquisition via Executive Supplemental Savings Plan (Dividend Reinvestment) |
| Dr H Barron | Non-Executive Director | 2022-08-18 | ADSs | $34.2500 | 61.000 | Acquisition via 401(k) Plan (Dividend Reinvestment) |
| Mr J Ford | SVP and Group General Counsel | 2022-08-18 | ADSs | $34.2500 | 57.564 | Acquisition via Executive Supplemental Savings Plan (Dividend Reinvestment) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. It serves solely as a regulatory disclosure of insider trading activity.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The transactions reported were automatic acquisitions resulting from dividend reinvestment plans.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of American Depositary Shares (ADSs) resulting from dividend reinvestment, not open-market purchases or sales.
- Transaction Price: All transactions occurred at a uniform price of $34.2500 per ADS on August 18, 2022.
- Exchange: Transactions were conducted on the New York Stock Exchange (XNYS).
- Participants: The filing covers two individuals: Dr H Barron (Non-Executive Director) and Mr J Ford (SVP and Group General Counsel).